Previously, Baum served at Pfizer as senior vice president for clinical research, and vice president and head of oncology, where he developed oncology drugs including tyrosine kinase inhibitors sunitinib (Sutent), axitinib (Inlyta) and crizotinib (Xalkori).
Baum also served at Schering-Plough and was responsible for the Phase I-IV development of several oncology compounds including temozolomide (Temodar).
MethylGene president and CEO Charles Baum said MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme, and MGCD265, an oral Met/VEGF receptor kinase inhibitor for patients with solid tumors, are developed based upon impressive science and encouraging early phase clinical data.
"We will continue to focus our efforts on realizing the potential of these novel therapies to address the unmet needs of patients with cancer and fungal infections," Baum added.
MethylGene board of directors chairman Martin Godbout said the company is delighted that Baum has been appointed at the important point in its development.
"His exceptional experience in drug development will be of tremendous value to the advancement of our oncology and antifungal programs," Godbout added.
"I would also like to extend my most sincere thanks to Mr. Louis Lacasse and Mr. Colin Mallet for their longstanding and dedicated support as members of our Board of Directors."